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AbstrACt
Introduction Osteoarthritis (OA) is a highly prevalent 
and disabling condition with limited safe and effective 
treatment options. Intra-articular therapies are increasingly 
being used, however whether the effect of these agents 
is due to active treatment or placebo remains unclear. As 
the placebo response can be attributed to multiple factors, 
assessment of the placebo response using individual 
patient data (IPD) meta-analysis will give insight into 
the different modifiers of response to placebo. The aim 
of this IPD meta-analysis is to investigate the predictors 
of placebo response in intra-articular injection trials in 
OA. IPD meta-analysis is considered to be superior to 
conventional meta-analysis, as it combines multiple trial 
data, facilitates the standardisation of analyses across 
different studies and allows measuring derivation of the 
desired information.
Method and analysis A systematic literature search will 
be conducted for randomised clinical trials comparing 
corticosteroid and viscosupplementation/hyaluronic 
acid intra-articular injections with placebo for knee and 
hip OA. Pubmed (Medline), EMBASE, Web of Science, 
Cochrane Central and SCOPUS will be searched from 
inception to September 2018. Corresponding authors of 
the original trials will be contacted to obtain IPD. Risk of 
bias will be assessed using the Cochrane Collaboration’s 
tool. The primary outcome will be change in pain from 
baseline. Secondary outcomes will be change in function 
and patient's global assessment. Potential predictors 
of placebo response assessed will include patient's 
characteristics, pain mechanism characteristics, 
radiographic severity, pain severity, intervention 
characteristics and trial design characteristics. A 
multilevel logistic regression analyses will be applied. 
Results will be reported using the Preferred Reporting 
Items for Systematic review and Meta-Analysis -IPD 
guidelines.
Ethics and dissemination  This study does not include 
identifiable data and ethical approval was obtained by the 
original investigators. Results of the IPD meta-analysis will 
be disseminated for publication in peer-reviewed journals 
and conference presentations.
PrOsPErO registration number CRD42018095188 
IntrOduCtIOn
Osteoarthritis (OA) is a highly preva-
lent condition that imposes a substantial 
burden on the individuals affected. It is 
estimated that by 2030, 25% of the popu-
lation of the USA (67 million adults) will 
have OA.1 Current management strategies 
suggest a focus towards conservative ther-
apies including physiotherapy and weight 
loss, as well as pain palliation whether it is in 
the form of medications or ultimately joint 
replacement surgery.2 However, for patients, 
especially with only symptomatic monoar-
thritis or oligoarthritis, the systematic effects 
of oral medications raises safety concerns.3–6 
strengths and limitations of this study
 ► The use of an individual patient data meta-analysis 
of randomised controlled trials (RCTs)  will provide 
more precise estimates of the placebo response. It 
also allows the identification of patient-level predic-
tors of placebo response in this population.
 ► The study will be conducted within the framework 
of the OA Trial Bank, an international organisation 
that initiates meta-analyses of effect on predefined 
subgroups of OA patients from existing trials.
 ► Identification of the predictors of placebo response in 
intra-articular injections for OA may influence future 
clinical trial designs with a more tailored approach 
when classifying participants in future studies.
 ► Inclusion of frequently utilised intra-articular injec-
tion RCTs will allow for a larger sample size, in-
creased precision of the results and provide insight 
into the more commonly used injectables.
 ► We have only included injections of corticoste-
roid and viscosupplements/hyaluronic acid trials 
because these are the standard intra-articular 
treatments for OA. There are other intra-articular 
injection treatments such as blood products, growth 
factors and prolotherapy. As they are not established 
treatments with limited evidence in OA, we will ex-
clude them from this study.
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Intra-articular injection therapies appear to be an attrac-
tive alternative in these patients, and there is a trend in 
the development of investigational intra-articular agents, 
aiming to improve symptoms and potentially alter disease 
progression.
Presently available intra-articular therapies are corti-
costeroids and viscosupplements (hyaluronic acid).7 8 
Agents such as blood-derived products are also available 
in some countries. However, based on current guidelines 
for knee OA, intra-articular injections are not first-line 
therapies and are preferred as the last non-operative 
alternative where other conservative modalities have 
failed, or in some published treatment guidelines, not 
recommended at all based on their limited evidence, or 
controversial efficacy profiles.9 10
There are a number of methodological limitations of 
clinical trials in OA that have constrained progress. Espe-
cially with intra-articular therapies in OA, most trials are 
small, thus affecting the strength of the studies. Another 
issue is the frequent practice of comparing one controver-
sial agent versus another (ie, platelet-rich plasma versus 
hyaluronate agent), which will not justify the agent to be 
superior in the overall treatment of OA. Furthermore, 
in intra-articular therapy trials, there are concerns of 
whether intra-articular injection of normal saline should 
be considered as the ideal agent to be employed as a 
placebo. There are increasing number of studies contrib-
uting to the evidence of intra-articular saline having a 
potential biological effect. The biological effect in this 
setting is likely secondary to neurobiological mechanisms 
such as those via endogenous opioid and dopaine,11 as 
well as via possible dilution of the inflammatory element 
in the joint because of the volume of saline.12 13 Thus, 
intra-articular saline as a placebo can be considered to be 
an ‘impure placebo’ in the context of a placebo-controlled 
intra-articular injection trial. The inclusion of a no-treat-
ment/sham-injection group may be a way to discern the 
placebo effect of saline injections, however the presence 
of this design is rare in OA clinical trials. Despite this, 
previous meta-analysis of randomised controlled trials 
(RCTs) assessing the placebo response across a range of 
therapies in OA (non-pharmacological, pharmacological 
and surgical treatments) have confirmed that placebo 
response (effect size (ES)=0.51 95% CI 0.46 to 0.55) 
is greater than no treatment or spontaneous response 
(ES=0.03, 95% CI −0.13 to 0.18) for pain in OA.14
The inability to demonstrate a minimum clinically 
important difference (MCID) over placebo, directly 
affects the development of potential pharmacological 
innovations and their translation to becoming commer-
cially available treatment options for this disabling disease. 
The magnitude of the placebo response in OA trials is 
significant with about 75% of treatment effect being 
attributable to placebo contextual effects.15 In general, 
the more invasive and more frequent the administra-
tion of an intervention, the larger the placebo response. 
For invasive therapies, patients’ expectations and beliefs 
create even larger placebo/contextual effects.14 When 
considering clinical trial design, the challenges of which 
placebo to choose, its volume, injection frequency, the 
use of injection guidance, concomitant local anaesthetic 
use, patient baseline disease presentation (bilateral vs 
unilateral disease, concomitant presence of inflamma-
tory features/effusion, disease severity, baseline pain) all 
create substantial opportunity for heterogeneity in what 
is already a challenging clinical trial environment. The 
intervention itself is also subject to contextual effects; 
administration route, colour, branding and cost all have 
an effect, thus indicating that clinical trials may need 
more standardisation across the board to optimise the 
demonstration of treatment response.16
To date, placebo responses from clinical trials are ulti-
mately measured as a change in outcome from baseline in 
the placebo group in comparison to the treatment group 
and is potentially confounded by spontaneous effects 
such as the Hawthorne effect (ie, the effect due to being 
observed), natural fluctuation of disease and regression to 
the mean.14 16 Minimal trials incorporate a no-treatment 
group, which may allow for adequate clarification of the 
placebo effect. Meta-analysis of OA treatments has shown 
that the placebo response varies greatly between individ-
uals.15 The main limitation of aggregate data meta-analysis 
is that the variations of the treatment/placebo responses 
across individuals cannot be scrutinised. As the placebo 
response can be attributed to the individual or related to 
the study protocol, assessment of the placebo response 
utilising individual patient data (IPD) meta-analysis 
will give insight into the different predictors of placebo 
response. IPD analysis is now increasingly used over estab-
lished meta-analysis and is considered to be superior, as 
it facilitates standardisation of analyses across different 
studies and allow derivation of the desired information.17 
Our IPD meta-analysis will examine the role of potential 
placebo response modifiers, assessing patient, interven-
tion and trial characteristics—contextual factors that are 
rarely measured and reported in clinical trials or analysed 
in existing meta-analyses.
This analysis will be conducted under the auspices of 
the OA Trial Bank, an international collaboration that 
is endorsed by the Osteoarthritis Research Society Inter-
national and the European League Against Rheumatism 
(EULAR). The OA Trial Bank was initiated in 2010 with 
the purpose of collecting and analysing IPD of published 
RCTs in OA to identify specific responseive subgroups for 
the different OA treatment. It brings together data from 
individuals with a diagnosis of OA, recruited for published 
RCTs from around the world to form a databank.18 19
Therefore, the aim of this IPD analysis is to investigate 
the predictors of placebo response in intra-articular injec-
tion trials in OA. This study will differ from the recently 
submitted IPD-meta-analysis protocol assessing placebo 
response in OA by University of Nottingham arthritis 
research group.19 Based on their published protocol, their 
data extraction from the OA Trial Bank is targeted at OA 
therapies namely topical non-steroidal anti-inflammatory 
drugs, topical capsaicin, glucosamine and intra-articular 
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glucocorticoids. Potential placebo response modifiers 
that will be assessed are: patient baseline characteristics 
(age, gender and body mass index), disease (radiographic 
information, signs of inflammation, muscle strength, 
duration of complaints, pain severity, type of pain, central 
sensitisation and psychological assessments), placebo 
(oral, topical, injection and dose) and trial and outcome 
measures (pain, function, patient global assessment and 
quality of life).19 In contrast, intra-articular injection ther-
apies will be the only therapies of interest in this analysis. 
While there will be some cross over regarding patient-level 
characteristics, the incorporation of viscosupplementa-
tion/hyaluronic acid trials and an updated systematic 
review with the acquisition of newer glucocorticoid trials 
which will allow for a larger sample size, increased preci-
sion of the results and provide insight into the more 
commonly used injectables. In addition to patient-level 
characteristics, there will be a focus on interventional 
and trial characteristics, that is, intervention characteris-
tics (aspirate volume, frequency of injection, volume of 
injection and intra-articular injection approach) and trial 
characteristics (clinical setting, blinding, use of intention 
to treat analysis and funder/sponsor).
MEthOds And AnAlysIs
IPD from trials comparing intra-articular injection to 
placebo for knee OA will be extracted and reanalysed to 
ascertain the magnitude of the placebo response and the 
role of potential predictors in these trials. The analysis 
will be conducted under the umbrella of the OA Trial 
Bank.
The IPD meta-analysis will be conducted in accordance 
with the methods recommended by the IPD Meta-anal-
ysis Methods Group.17 Reporting of the meta-analysis will 
conform with the Preferred Reporting Items for System-
atic review and Meta-Analysis (PRISMA)-IPD checklist.20
The research question and study proposal of this study 
has been approved by the steering committee of the OA 
Trial Bank, before the development of the full study 
protocol.
Participants
Participants from the identified RCTs must have a diag-
nosis of knee and hip OA, according to the criteria 
defined by the American College of Rheumatology, 
EULAR evidence-based recommendations for the diag-
nosis of knee OA21 22 or fulfil specified radiological 
criteria of OA diagnosis.
types of baseline assessments
Participant baseline characteristics including age, gender, 
bilateral versus unilateral disease, other joint OA involve-
ment, radiographic severity, pain severity at baseline and 
presence of inflammatory features (based on imaging 
and physical examination). Intervention characteristics 
(clinical setting, aspirate volume, frequency of injec-
tion, volume of injection and intra-articular injection 
approach) and trial design characteristics (blinding, 
dropout rate, use of intention to treat analysis, role of 
funder/sponsor) will also be extracted.
types of outcomes
The primary outcome of the IPD meta-analysis will be 
change in pain over time. Visual analogue scale (VAS) 
pain score will be preferentially used for the analysis. If 
unavailable, the Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) pain score will be 
used and converted into a VAS 0–100 scale as per previous 
OA Trial Bank Protocols.23
Secondary outcomes will be a change in function and 
patient global assessment.
language
No language restrictions will apply.
literature search
Identification of studies
A systematic literature search will be conducted using the 
following databases: Pubmed (Medline), EMBASE, Web 
of Science, Cochrane Central and SCOPUS. The search 
will be from inception to September 2018. The search 
strategy was developed by the reviewers in consultation 
with the OA Trial Bank (online supplementary appendix 
1).
Literature searches will be done separately for intra-ar-
ticular glucocorticoid and viscosupplementation/hyal-
uronic acid. The literature search approach will comprise 
of an amalgamation of main search terms including iden-
tification of the OA population group, intervention of 
intra-articular glucocorticoid and viscosupplementation/
hyaluronic acid and of RCT design. Furthermore, efforts 
will be made to identify unpublished trials through  Clini-
caltrials. gov, European Union Clinical Trials Register and 
International Standard Randomised Controlled Trials 
Number (ISRCTN) registry and contacting pharmaceu-
tical suppliers.
Identified studies will be imported to EndNote X8 for 
screening.
Screening process
Studies eligible for inclusion will be assessed by two inde-
pendent reviewers (SY and LD). Titles and abstracts for 
potential studies will be screened first, and subsequently, 
the full text of the selected studies will be reviewed for 
appropriateness to be included. If no consensus is reached, 
a third reviewer will be consulted (DJH). The results will 
be summarised as per the PRISMA guidelines.24
type of studies
Randomised placebo-controlled trials of intra-articular 
glucocorticoids and/or viscosupplementation/hyal-
uronic acid in knee or hip OA will be included. Studies 
related to inflammatory arthritis (such as rheumatoid 
or psoriatic arthritis) will be excluded. Animal model 
and biomarker studies will be excluded. Trials that are 
not randomised, literature or systematic reviews, and 
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conference abstracts without available data will be 
excluded.
data collection and transfer
As per all other studies conducted by the OA Trial 
Bank,18 23 25 the same method for data acquisition and 
transfer will be utilised. The corresponding authors 
of eligible trials will be invited to collaborate. Initial 
contact will be by email with two further successive email 
reminders. If the corresponding author is uncontactable, 
communication will be attempted with the other trial 
authors and/or institutions listed. Authors who are willing 
to collaborate will be asked to sign a data delivery agree-
ment from the OA Trial Bank. This will include items of 
input data, ownership of data, obligation, terms, author-
ship and subsequent publication intentions. The data 
obtained will be stored on a secure server at Erasmus MC 
University Medical Center, Rotterdam, the Netherlands, 
and participant details will be kept in an anonymous and 
confidential fashion. Data quality will be ensured through 
independent checking looking at data-entry mistakes and 
inconsistencies. Data received will be compared with the 
published summary results from the primary studies. In 
situations where there are differences found, the authors 
will be contacted to resolve the discrepancy issue.
With the existing intra-articular glucocorticoid trials 
that have been stored in the OA Trial Bank, the corre-
sponding authors will be contacted and will be asked to 
sign a further data transfer agreement for the use of their 
data for the purpose of this analysis.
Patient and public involvement
There have been no patient and/or public involvement 
in the design of this IPD meta-analysis.
risk and quality assessment
The included trials will be assessed independently by two 
reviewers to assess the quality of evidence and the risk of 
biases through the use of the Cochrane Collaboration’s 
tool.26 27 A third reviewer will be consulted if there is a 
disagreement. The domains assessed will include rando-
misation of procedure, blinding of participants, physi-
cians and treatment allocation, use of intention to treat 
analysis, incomplete outcome data, baseline group simi-
larity, reporting bias and other sources of biases. Studies 
will be categorised as ‘low risk’, ‘high risk’ or ‘unclear. As 
per previous studies with the OA trial bank, a low risk of 
bias study will be classified as fulfilling at least 6 of the 12 
items in the Cochrane Collaboration’s tool.27
data analysis
A descriptive evaluation of each trial and study partici-
pants will be conducted. Publication bias will be investi-
gated using a funnel plot analysis as this will specify the 
potential impact of both known and unknown missing 
trials on the results.27 28 Missing data will be assumed to 
be missing at random, thus patient characteristics will be 
used to impute missing data by means of multiple imputa-
tion at random.29 30 In addition, we will compare the ESs 
pooled from those responded versus the overall (ie, the 
ES pooled from all trials systematically searched from the 
literature) to examine the deviation.
Baseline and follow-up data from the placebo arm 
will be used to estimate the predictors of the placebo 
response. Separate analyses will be conducted for gluco-
corticoids and viscosupplementation/hyaluronic acid, as 
well as different outcome measures (ie, pain, function 
and patient global assessment). Trials will also be grouped 
by type of joint (ie, knee or hip) and follow-up duration 
(eg, <4 weeks or ≥4 weeks for corticosteroid and <12 weeks 
or ≥12 weeks for viscosupplementation/hyaluronic acid).
A one-step approach will be applied, via the use of 
multilevel regression models to assess for predictors of 
the placebo response. The use of the one step approach 
in this setting will allow for a more cohesive modelling of 
Table 1 Potential placebo response modifiers
Study features Description
Patient domain Age 
Gender 
Body mass index 
Bilateral versus unilateral disease 
Disease duration 
 Pain 
mechanisms 
Central pain mechanisms: 
  Osteoarthritis in other joints. 
  Comorbidities. 
  Pain severity. 
Peripheral pain mechanisms: 
  Radiographic information. 
  Presence of inflammatory features 
(ultrasound versus physician assessed 
joint swelling). 
  Morning stiffness symptoms. 
Intervention 
characteristics 
Clinical setting (ie, location of intervention) 
Aspirate volume 
Frequency of injection 
Volume of injection 
Intra-articular injection approach (ie, medial 
vs lateral approach, use of ultrasound 
guided injection) 
Blinding 
Dropout rates per group 
Inclusion of a ‘no treatment’ group 
Use of ‘intention to treat analysis’ 
Randomisation ratio 
Trial duration
Single centre/multicentre study 
Parallel/crossover trial 
Funding/sponsor (ie, pharmaceutical 
funding) 
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covariates and account for the clustering of participants 
within the study.17 This will be done by combining all 
the data from all the studies available after appropriate 
standardisation of the variables and a new dataset will 
be formed to allow for further analysis. To assess for the 
potential subgroup effects, a random effect model will 
be utilised given the hierarchical nature of the data to 
assess the interaction effects, with change in pain being a 
dependent variable and potential predictors being inde-
pendent variables. In the setting where a no-treatment 
control is available, we will include placebo-no-treatment 
as an independent variable. Responders to placebo will 
be compared with non-responders to identify predictors 
of response.
The primary outcome will be change in pain from base-
line and will be determined as the dependent variable in 
the regression model. The MCID threshold will be a 20% 
or more reduction in pain based on the VAS pain score 
with 0 mm being no pain to 100 mm being the worst pain 
ever. This level has been recommended for use in pain 
and function assessment in rheumatic diseases such as 
OA,31 32 and we will use it to define the placebo response 
which is equivalent to an ES of 0.8,33 that indicates the 
response unlikely to be caused by spontaneous effects. In 
situations where WOMAC pain score is only available, it 
will be used instead.
Secondary outcomes will be a change in function and 
patient global assessment. Change in pain will be deter-
mined as the dependent variable, and independent vari-
ables will be the potential predictors of placebo response. 
These will be grouped as patient-level characteristics, 
peripheral pain mechanisms, central pain mechanisms, 
intervention characteristics and those related to trial 
design (blinding, funder/sponsor roles and intention to 
treat) (table 1) and are as listed below. Each group will 
be forced into multivariate models with a final model 
including all groups.
1. Patient characteristics: age, gender, body mass index, 
bilateral versus unilateral disease and disease duration.
2. Pain mechanisms: peripheral pain mechanisms (ie, 
signs of inflammation, morning stiffness symptoms 
and radiographic findings), central pain mechanisms 
(ie, other joint OA, comorbidities and pain severity).
3. Intervention characteristics: clinical setting (ie, loca-
tion of intervention), aspirate volume, frequency of 
injection, volume of injection, and intra-articular in-
jection approach (ie, medial vs lateral approach and 
use of ultrasound-guided injection).
4. Trial characteristics: blinding (patients, assessors or 
physicians), dropout rates, role of funder/sponsor 
(ie, pharmaceutical company), randomisation ratio, 
trial duration, single centre/multicentre study, par-
allel/cross-over trial and use of ‘intention to treat’ 
analysis.
The trials that originate the IPD will also be coded and 
included as a level variable in all analyses. ESs and 95% CI 
will be generated for each outcome measure. P<0.05 will 
be considered statistically significant.
A sensitivity analysis will be conducted using pain scores 
(instead of change in pain scores) as a continuous depen-
dent variable and repeating the approaches described 
above.
Statistical analyses will be performed using Stata SE 
V.14.
ExPECtEd rEsEArCh COntrIbutIOn
It is envisaged that the investigators will deliver data to 
be used in the design and execution of future clinical 
trials. It will allow for better understanding of the placebo 
response and subsequent implementation of clinical 
designs with lowered placebo responses.
EthICs And dIssEMInAtIOn
This study does not include identifiable data. Ethical 
approval was obtained by the original investigators. 
Results of the IPD meta-analysis will be disseminated for 
publication in a peer-reviewed journal and by interna-
tional conference presentations.
Author affiliations
1Department of Rheumatology, Royal North Shore Hospital, University of Sydney, 
Sydney, New South Wales, Australia
2Department of Rheumatology, Institute of Bone and Joint Research, University of 
Sydney, St Leonards, New South Wales, Australia
3Erasmus MC University Medical Center, Rotterdam, The Netherlands
4Department of General Practice, Erasmus University Medical Centre, Rotterdam, 
The Netherlands
5Division of Academic Rheumatology, University of Nottingham, Nottingham, 
Nottingham, UK
Contributors Study design: SP-CY, MLF, SMAB-Z, MvM, WZ and DJH contributed 
to the study design. SP-CY and LAD will be conducting the systematic review, data 
extraction and analysis. SP-CY drafted the first version of the manuscript and all 
the authors were involved in the critical revision of the manuscript for important 
intellectual content. The study proposal has been peer-reviewed and approved by 
the OA Trial Bank Steering Committee.
Funding SP-CY holds a University of Sydney Postgraduate Research Scholarship 
(Part Time). MLF holds a National Health and Medical Research Council (NHMRC) 
Career Development Fellowship and is a Sydney Medical Foundation Fellow. DJH 
holds an NHMRC Practitioner Fellowship. SMAB-Z reports grants from European 
Union, The Netherlands Organisation for Health Research and Development, Dutch 
Arthritis Foundation. WZ is supported by a grant from Arthritis Research UK. The OA 
Trial Bank is supported by the Dutch Arthritis Society. 
Competing interests DJH reports personal fees from consulting fees from Merck 
Serono, Flexion and Tissuegene, outside the submitted work. All other authors have 
nothing to disclose. 
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Hunter DJ, Bowden JL. Therapy: Are you managing osteoarthritis 
appropriately? Nat Rev Rheumatol 2017;13:703–4.
 o
n
 11 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027372 on 24 May 2019. Downloaded from 
6 Yu SP-C, et al. BMJ Open 2019;9:e027372. doi:10.1136/bmjopen-2018-027372
Open access 
 2. Hunter DJ, Schofield D, Callander E. The individual and 
socioeconomic impact of osteoarthritis. Nat Rev Rheumatol 
2014;10:437–41.
 3. Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids 
for osteoarthritis: a meta-analysis of randomized controlled trials. 
Osteoarthritis Cartilage 2007;15:957–65.
 4. Mitchell HL, Hurley MV. Management of chronic knee pain: a survey 
of patient preferences and treatment received. BMC Musculoskelet 
Disord 2008;9:123.
 5. Gore M, Sadosky AB, Leslie DL, et al. Therapy switching, 
augmentation, and discontinuation in patients with osteoarthritis and 
chronic low back pain. Pain Pract 2012;12:457–68.
 6. Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of 
paracetamol for spinal pain and osteoarthritis: systematic review 
and meta-analysis of randomised placebo controlled trials. BMJ 
2015;350:h1225.
 7. Bennell KL, Hunter DJ, Hinman RS. Management of osteoarthritis of 
the knee. BMJ 2012;345:e4934.
 8. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for 
the non-surgical management of knee osteoarthritis. Osteoarthritis 
Cartilage 2014;22:363–88.
 9. Hochberg MC, Altman RD, April KT, et al. American College 
of Rheumatology 2012 recommendations for the use of 
nonpharmacologic and pharmacologic therapies in osteoarthritis of 
the hand, hip, and knee. Arthritis Care Res 2012;64:465–74.
 10. Jevsevar DS, Brown GA, Jones DL, et al. The american academy 
of orthopaedic surgeons evidence-based guideline on: Treatment 
of osteoarthritis of the knee, 2nd edition. J Bone Joint Surg Am 
2013;95:1885–6.
 11. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and 
ethical advances of placebo effects. Lancet 2010;375:686–95.
 12. Saltzman BM, Leroux T, Meyer MA, et al. The therapeutic effect 
of intra-articular normal saline injections for knee osteoarthritis: 
A meta-analysis of evidence level 1 studies. Am J Sports Med 
2017;45:2647–53.
 13. Altman RD, Devji T, Bhandari M, et al. Clinical benefit of intra-
articular saline as a comparator in clinical trials of knee osteoarthritis 
treatments: A systematic review and meta-analysis of randomized 
trials. Semin Arthritis Rheum 2016;46:151–9.
 14. Zhang W, Robertson J, Jones AC, et al. The placebo effect and 
its determinants in osteoarthritis: meta-analysis of randomised 
controlled trials. Ann Rheum Dis 2008;67:1716–23.
 15. Zou K, Wong J, Abdullah N, et al. Examination of overall treatment 
effect and the proportion attributable to contextual effect in 
osteoarthritis: meta-analysis of randomised controlled trials. Ann 
Rheum Dis 2016;75:1964–70.
 16. Abhishek A, Doherty M. Mechanisms of the placebo response in pain 
in osteoarthritis. Osteoarthritis Cartilage 2013;21:1229–35.
 17. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual 
participant data: rationale, conduct, and reporting. BMJ 
2010;340:c221.
 18. van Middelkoop M, Arden NK, Atchia I, et al. The OA Trial Bank: 
meta-analysis of individual patient data from knee and hip 
osteoarthritis trials show that patients with severe pain exhibit greater 
benefit from intra-articular glucocorticoids. Osteoarthritis Cartilage 
2016;24:1143–52.
 19. Fu Y, Persson MS, Bhattacharya A, et al. Identifying placebo 
responders and predictors of response in osteoarthritis: a protocol 
for individual patient data meta-analysis. Syst Rev 2016;5:183.
 20. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for 
systematic review and meta-analysis protocols (PRISMA-P) 2015: 
elaboration and explanation. BMJ 2015;350:g7647.
 21. Altman R, Asch E, Bloch D, et al. Development of criteria for the 
classification and reporting of osteoarthritis. Classification of 
osteoarthritis of the knee. Diagnostic and Therapeutic Criteria 
Committee of the American Rheumatism Association. Arthritis 
Rheum 1986;29:1039–49.
 22. Zhang W, Doherty M, Peat G, et al. EULAR evidence-based 
recommendations for the diagnosis of knee osteoarthritis. Ann 
Rheum Dis 2010;69:483–9.
 23. van Middelkoop M, Dziedzic KS, Doherty M, et al. Individual patient 
data meta-analysis of trials investigating the effectiveness of 
intra-articular glucocorticoid injections in patients with knee or hip 
osteoarthritis: an OA Trial Bank protocol for a systematic review. Syst 
Rev 2013;2:54.
 24. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. BMJ 
2009;339:b2535.
 25. Runhaar J, Rozendaal RM, van Middelkoop M, et al. Subgroup 
analyses of the effectiveness of oral glucosamine for knee and 
hip osteoarthritis: a systematic review and individual patient 
data meta-analysis from the OA trial bank. Ann Rheum Dis 
2017;76:1862–9.
 26. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane 
Collaboration's tool for assessing risk of bias in randomised trials. 
BMJ 2011;343:d5928.
 27. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews 
of Interventions: The Cochrane Collaboration, 5.1.0 (updated March 
2011). 2011. http:// handbook. cochrane. org.
 28. Sterne JA, Gavaghan D, Egger M. Publication and related bias 
in meta-analysis: power of statistical tests and prevalence in the 
literature. J Clin Epidemiol 2000;53:1119–29.
 29. Donders AR, van der Heijden GJ, Stijnen T, et al. Review: a gentle 
introduction to imputation of missing values. J Clin Epidemiol 
2006;59:1087–91.
 30. Koopman L, van der Heijden GJ, Hoes AW, et al. Empirical 
comparison of subgroup effects in conventional and individual 
patient data meta-analyses. Int J Technol Assess Health Care 
2008;24:358–61.
 31. Groenwold RH, Donders AR, van der Heijden GJ, et al. Confounding 
of subgroup analyses in randomized data. Arch Intern Med 
2009;169:1532–4.
 32. Tubach F, Ravaud P, Martin-Mola E, et al. Minimum clinically 
important improvement and patient acceptable symptom state in 
pain and function in rheumatoid arthritis, ankylosing spondylitis, 
chronic back pain, hand osteoarthritis, and hip and knee 
osteoarthritis: Results from a prospective multinational study. 
Arthritis Care Res 2012;64:1699–707.
 33. Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, 
or placebo in patients with osteoarthritis of hip or knee: network 
meta-analysis. BMJ 2010;341:c4675.
 o
n
 11 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027372 on 24 May 2019. Downloaded from 
